Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis

Multiple myeloma (MM) is a malignant, clonal proliferative disease of plasma cells that remains incurable. This paper aims to analyze the current research status and emerging trends in immunotherapy for MM through bibliometric methods, thereby providing valuable references and guidance for future research and clinical practice. This study presents a bibliometric analysis of 1,018 English-language publications related to MM immunotherapy, which were published in the Web of Science (WoS) Core Collection database from 2013 to 2023. VOSviewer and CiteSpace were employed to visualize the research hotspots and trends within the field of MM immunotherapy. The United States had the highest number of publications (n = 432, 42.44%), followed by China (n = 177, 17.39%). Harvard University was the institution with the most publications (n = 85), while Anderson KC (n = 27) was the most prolific researcher in the field. The highly cited literature mainly focuses on the treatment regimen based on daratumumab, the application of BCMA CAR-T therapy and the management of relapsed/refractory MM (RRMM), which represent the current research hotspots in this field. Burst detection highlights that bispecific antibodies and preclinical activity as key areas of interest. The cooperation among countries, institutions, and authors in this field should be strengthened. The treatment regimen utilizing daratumumab, the implementation of BCMA CAR-T therapy, and the management of RRMM represent significant research focal points in this field. Additionally, the development and application of bispecific antibodies have emerged as a frontier in recent years.